Loss of special education program has some Robbinsdale students unsure of future
A Twin Cities family is facing a difficult decision because of school budget cuts.
Earlier this spring, Robbinsdale Area Public Schools said a budgeting error led to a $21 million deficit, forcing them to cut more than 200 staff members and teachers.
"Vehicles are his favorite. All day long he talks about them. He takes apart his vehicles. All day long I find little wheels everywhere," said Cassidy Landman about her son, Athan.
Athan Landman has faced plenty of challenges during his seven years of life. He's been diagnosed with autism and ADHD and he missed kindergarten because of a serious health issue.
"They found out he has the rare brain disease, moyamoya," said Cassidy Landman.
But the Landmans said that even when their son was in the hospital, his teacher Katherine Hibbs would visit.
"Legitimately one of the greatest teachers out there right now," said Sean Landman, Athan's dad.
Hibbs is a special needs teacher in the WAVE program at Zachary Lane Elementary in Plymouth. When Athan Landman finally got to school, the Landmans said WAVE made the transition much easier.
"He came up and was like, 'Hey, I made a friend today.' And I started tearing up like, 'You made a friend today buddy? That's awesome,'" said Sean Landman.
But now the Landmans believe the teacher, the program and the school their son has adapted to are being taken away, in part because of Robbinsdale's budget shortfall.
"These kids need consistency and this is not consistent," said Cassidy Landman.
The school district has confirmed that WAVE will no longer be at Zachary Lane, but the program will continue at other schools. They said the decision was not driven by budget reductions, but rather by a "responsibility to provide appropriate high quality services for students with disabilities."
For Athan Landman's family, it's all about the unknown at this point. They said they still don't have confirmation on where his next school will be or what kind of program will be available to him.
And they say their son needs time to adapt. They worry this will be the start of Athan Landman and other special needs students moving from school to school each year.
"I feel frustrated. I feel very frustrated for my son," said Cassidy Landman.
The Landmans said they started receiving newsletters from another elementary school, but haven't been told that's the school their son is being moved to.
If Athan Landman is moved, the family said they'll look to move to another district or homeschool.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29-05-2025
- Yahoo
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET. A live webcast of this presentation can be accessed by visiting 'Investor Events' on the Investors section of the Wave Life Sciences website: A replay of this presentation will be archived and available on the site for a limited time following the event. About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, as well as several preclinical programs utilizing the company's broad RNA therapeutics toolkit. Driven by the calling to 'Reimagine Possible', Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn. Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827 Investors:InvestorRelations@ Media:MediaRelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
01-05-2025
- CBS News
Loss of special education program has some Robbinsdale students unsure of future
A Twin Cities family is facing a difficult decision because of school budget cuts. Earlier this spring, Robbinsdale Area Public Schools said a budgeting error led to a $21 million deficit, forcing them to cut more than 200 staff members and teachers. "Vehicles are his favorite. All day long he talks about them. He takes apart his vehicles. All day long I find little wheels everywhere," said Cassidy Landman about her son, Athan. Athan Landman has faced plenty of challenges during his seven years of life. He's been diagnosed with autism and ADHD and he missed kindergarten because of a serious health issue. "They found out he has the rare brain disease, moyamoya," said Cassidy Landman. But the Landmans said that even when their son was in the hospital, his teacher Katherine Hibbs would visit. "Legitimately one of the greatest teachers out there right now," said Sean Landman, Athan's dad. Hibbs is a special needs teacher in the WAVE program at Zachary Lane Elementary in Plymouth. When Athan Landman finally got to school, the Landmans said WAVE made the transition much easier. "He came up and was like, 'Hey, I made a friend today.' And I started tearing up like, 'You made a friend today buddy? That's awesome,'" said Sean Landman. But now the Landmans believe the teacher, the program and the school their son has adapted to are being taken away, in part because of Robbinsdale's budget shortfall. "These kids need consistency and this is not consistent," said Cassidy Landman. The school district has confirmed that WAVE will no longer be at Zachary Lane, but the program will continue at other schools. They said the decision was not driven by budget reductions, but rather by a "responsibility to provide appropriate high quality services for students with disabilities." For Athan Landman's family, it's all about the unknown at this point. They said they still don't have confirmation on where his next school will be or what kind of program will be available to him. And they say their son needs time to adapt. They worry this will be the start of Athan Landman and other special needs students moving from school to school each year. "I feel frustrated. I feel very frustrated for my son," said Cassidy Landman. The Landmans said they started receiving newsletters from another elementary school, but haven't been told that's the school their son is being moved to. If Athan Landman is moved, the family said they'll look to move to another district or homeschool.
Boston Globe
26-03-2025
- Boston Globe
Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success
In Wave's Phase 2 study, 11 patients taking the company's treatment began producing an average of 7.8 percent of normal dystrophin, But perhaps more notably, Wave touted that the drug also appears to improve muscle health. The group of children taking the drug had a 28.6 percent reduction in muscle fibrosis compared to historical data. Advertisement Wave plans to submit the drug to the FDA for approval next year. The company has tested multiple Duchenne drugs since its founding in 2012, largely with Wave's drug is designed for a subset of Duchenne patients who have problems with exon 53, which is an Wave's drug is part of a new generation of so-called 'exon skippers' being developed for the fatal disease. The first such treatment, also made by Sarepta, was Biotechs such as Dyne, Wave, and Avidity are now developing more precise skippers that are either targeted to muscle or tweaked in other ways to improve efficacy.
